Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingchuang Ointment is a Traditional Chinese Medicine (TCM) topical formulation specifically developed for the management of chronic, non-healing wounds such as diabetic foot ulcers, pressure sores, and vasculitic ulcers. Developed primarily by the Tianjin Medical University Metabolic Diseases Hospital, it is composed of several herbal components including *Sanguisorba officinalis* (Di Yu), *Phellodendron amurense* (Huang Bai), and *Borneolum Syntheticum* (Bing Pian). The therapeutic effect is attributed to its ability to modulate the wound microenvironment by inhibiting pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reducing the activity of matrix metalloproteinases (MMPs), and promoting the expression of growth factors like VEGF and TGF-β. These actions collectively enhance angiogenesis, fibroblast proliferation, and collagen synthesis, facilitating the transition from the inflammatory phase to the proliferative phase of wound healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jingchuang Ointment.